A Multicenter, Randomized, Phase III Trial of Chemotherapy Followed by 6-month or 12-month Icotinib Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation
Phase of Trial: Phase III
Latest Information Update: 03 Sep 2018
Price : $35 *
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ICTAN
- 31 Aug 2018 Biomarkers information updated
- 25 Aug 2018 Planned number of patients changed from 477 to 318.
- 19 Apr 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2020.